


Domain Therapeutics signs multi-target research collaboration with Boehringer Ingelheim

05 December 2018 | News

Domain Therapeutics' unique platform technologies will be used to identify novel treatment approaches for neuropsychiatric diseases



Domain Therapeutics announces a multi-target drug discovery collaboration and licensing agreement with Boehringer Ingelheim on orphan G Protein-Coupled Receptors (GPCRs) in the Central Nervous System (CNS) disease area.

The collaboration combines the expertise of Domain Therapeutics, a French and Canadian biopharmaceutical company, in the discovery of GPCR targeting drugs in CNS, oncology and immuno-oncology, with Boehringer Ingelheim's expertise in the discovery and clinical development of therapeutics on multiple indications.

Domain Therapeutics will use its proprietary platforms, DTect-All[™] and bioSens-All[™], which enable a comprehensive characterization of small molecule GPCR binders for the screening and characterization of potential lead compounds. In addition, Domain brings on board its extensive network of leading GPCR experts to provide additional knowledge and insight to the discovery phase (Prof. Brigitte Kieffer, Douglas Institute – Montreal, Canada and Prof. Michel Bouvier, IRIC Institute - Montreal, Canada).

Domain will be eligible for an upfront payment, discovery, development and commercial milestone payments as well as royalties on sales. Financial details are not disclosed.